Online citations, reference lists, and bibliographies.
← Back to Search

Adjuvant Docetaxel For Node-positive Breast Cancer.

M. Martín, T. Pieńkowski, John Mackey, M. Pawlicki, J. Guastalla, Charles T. Weaver, E. Tomiak, T. Al-Tweigeri, L. Chap, É. Juhos, R. Guévin, A. Howell, T. Fornander, J. Hainsworth, R. Coleman, J. Vinholes, M. Modiano, T. Pintér, S. C. Tang, B. Colwell, C. Prady, L. Provencher, D. Walde, Á. Rodríguez-Lescure, J. Hugh, C. Loret, M. Rupin, S. Blitz, P. Jacobs, M. Murawsky, A. Riva, C. Vogel
Published 2005 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
BACKGROUND We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer. METHODS We randomly assigned 1491 women with axillary node-positive breast cancer to six cycles of treatment with either TAC or FAC as adjuvant chemotherapy after surgery. The primary end point was disease-free survival. RESULTS At a median follow-up of 55 months, the estimated rates of disease-free survival at five years were 75 percent among the 745 patients randomly assigned to receive TAC and 68 percent among the 746 randomly assigned to receive FAC, representing a 28 percent reduction in the risk of relapse (P=0.001) in the TAC group. The estimated rates of overall survival at five years were 87 percent and 81 percent, respectively. Treatment with TAC resulted in a 30 percent reduction in the risk of death (P=0.008). The incidence of grade 3 or 4 neutropenia was 65.5 percent in the TAC group and 49.3 percent in the FAC group (P<0.001); rates of febrile neutropenia were 24.7 percent and 2.5 percent, respectively (P<0.001). Grade 3 or 4 infections occurred in 3.9 percent of the patients who received TAC and 2.2 percent of those who received FAC (P=0.05); no deaths occurred as a result of infection. Two patients in each group died during treatment. Congestive heart failure and acute myeloid leukemia occurred in less than 2 percent of the patients in each group. Quality-of-life scores decreased during chemotherapy but returned to baseline levels after treatment. CONCLUSIONS Adjuvant chemotherapy with TAC, as compared with FAC, significantly improves the rates of disease-free and overall survival among women with operable node-positive breast cancer.
This paper references
Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology.
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
J. Nabholtz (2003)
Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer.
B. Fisher (1995)
Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.
G. Pauletti (1996)
For personal use only. No other uses without permission. Copyright © 2005 Massachusetts Medical Society. All rights reserved
Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.
L. Gianni (1997)
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
H. Bear (2003)
671 Phase III study comparing AT (Adriamycin, Docetaxel) to FAC (Fluorouracil, Adriamycin, Cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC)
M. Bontenbal (2003)
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
H. Parnes (2003)
Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
D. Persons (1997)
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedioneresistant breast cancer
Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study
R. Elledge (2000)
Soc Clin Oncol
HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement.
T. Jacobs (2000)
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
I. C. Henderson (2003)
A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project
R. Smalley (1977)
Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization
Persons Dl (1997)
Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.
A. Goldhirsch (2003)
The concordance between the clinical trials assay ( CTA ) and fluorescence in situ hybridization in the Herceptin pivotal trials
RD Mass (2000)
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
A. Buzdar (2002)
Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
J. Aisner (1987)
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracyclineresistant metastatic breast cancer
Doxorubicin ( DOX ) and Taxotere ( TXT ) — a pharmacokinetic ( PK ) study of the combination in advanced breast cancer
J Schüller (1998)
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
P. Ravdin (1995)
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
R. Peto (1977)
J Clin Oncol
Taxo - tere ( T ) does not change the pharmacokinetic ( PK ) profile of doxorubicin ( dox ) and doxorubicinol ( Dx - ol )
R Bellot (1998)
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.
H. Ozer (2000)
Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe
B. Fisher (1990)
Toxicity and health-related quality of life (HRQoL) in node-negative breast cancer (BC) patients (pts) receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide): Impact of adding prophylactic growth factors (GF) to TAC. GE
M. Martín (2005)
Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
P. Fumoleau (2003)
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
M. Citron (2003)
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
M. Martín (2003)
Proc Am Soc Clin Oncol
The taxanes : paclitaxel and docetaxel
Nabholtz J-M (2003)
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.
R. Peto (1976)
Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic.
J. Gehl (1996)
[Estrogen receptor (ER), progesterone receptor (PR)].
Tatsuo Sawada (2005)
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
V. Valero (1995)
Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
J. Nabholtz (2001)
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
S. Chan (1999)

This paper is referenced by
Traitement adjuvant du cancer du sein n’exprimant pas HER2
J. Pierga (2007)
International Doctorate Program in Molecular Oncology and Endocrinology Doctorate School in Molecular Medicine
V. Forestieri (2007)
Docetaxel in combination therapy for node-positive, early-stage breast cancer
M. Martín (2006)
Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer
S. Kuemmel (2006)
Evolution of adjuvant chemotherapy for breast cancer
G. Minckwitz (2015)
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
A. Roth (2007)
Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
S. Ward (2007)
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
T. Grushko (2008)
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.
F. Penault-Llorca (2009)
Cannulation of the impalpable section of radial artery: preliminary clinical and ultrasound observations
A. P. Gratrix (2009)
Adjuvant Systemic Therapy for Breast Cancer: An Overview
Virginia Kaklamani (2010)
Herceptin in early breast cancer: a call for judicious use.
M. Thorat (2005)
Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
R. C. Coombes (2011)
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
A. Goldhirsch (2005)
Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
M. Levine (2005)
Maximising, outcomes in adjuvant breast cancer
J. Crown (2006)
Adjuvant systemic therapy for operable breast cancer.
S. Narayanan (2007)
Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy.
M. Wampler (2007)
Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis
M. Debled (2007)
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
M. Martín (2008)
Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.
H. Chew (2009)
Cancer du sein et grossesse
E. Vinatier (2009)
Resultados definitivos de un ensayo de adyuvancia fase III para comparar tres regímenes de quimioterapia en mujeres con cáncer de mama con ganglios positivos operable: estudio NSABP B-38
S. Swain (2013)
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
Hodgkin Lymphoma (2014)
Systematic Review of the Risk of Permanent Alopecia with DocetaxelTreatment for Breast Cancer
Shirin Nezafat Namini (2016)
Benefit risk assessment and update on the use of docetaxel in the management of breast cancer
S. Alken (2013)
Adjuvant Chemotherapy in Breast Cancer
E. Lim (2015)
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
J. Blum (2017)
Efficacy of reduced dose of pegfilgrastim in Japanese breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide therapy
Yoshio Mizuno (2017)
Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.
M. Trudeau (2005)
Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia.
A. Altwairgi (2013)
Evaluación del índice proteína-creatinina en orina aislada para la predicción de proteinuria significativa durante la gestación
L. G. D. G. Romualdo (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar